Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* GAD diagnosis by structured interview~* Hamilton Anxiety Scale score of 18 or MORE~* Clinical Global Impressions Severity Scale score of at least 4~* Hamilton Depression Scale score of 18 or less~* Hamilton Depression Scale suicide item score less than 2~* Use of an effective form of contraception throughout the study~Exclusion Criteria:~* Hypersensitivity to venlafaxine XR~* History of seizures~* Episode of major depressive disorder in the previous 6 months~* History of any psychotic illness, bipolar disorder, or dementia~* Substance abuse and dependence during the past 6 months~* Other anxiety disorders with the exception of social phobia as long as GAD is primary~* Regular use of anxiolytics or antidepressants within 7 days of study onset~* Use of fluoxetine or monoamine oxidase inhibitors within 28 days of study onset (low dose usage of benzodiazepines will not prevent participation)~* Use of other psychotropic medication besides benzodiazepines during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label Group (Type: ACTIVE_COMPARATOR): 6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
- Double-Blind Drug Group (Type: ACTIVE_COMPARATOR): 6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
- Double-Blind Placebo Group (Type: PLACEBO_COMPARATOR): 6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
- Double-Blind Drug-After-Drug Group (Type: ACTIVE_COMPARATOR): 6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
- Double-Blind Placebo-After-Drug Group (Type: PLACEBO_COMPARATOR): 6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
- Double-Blind Placebo-After-Placebo Group (Type: PLACEBO_COMPARATOR): 6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).